Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Apr;69(4):721–725. doi: 10.1038/bjc.1994.136

Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.

M Gion 1, M Plebani 1, R Mione 1, C Penzo 1, S Meo 1, A Burlina 1
PMCID: PMC1968804  PMID: 8142260

Abstract

We carried out a comparison of three commonly used mucin markers, CA549, CA15.3 and MCA. Serum samples from 184 healthy women and 237 patients with primary breast cancer were evaluated. The markers were measured using commercially available immunometric assays. Like CA15.3 and MCA, CA549 was significantly associated with tumour size and lymph node status, being an effective indicator of tumour bulk. CA549 was significantly correlated with both CA15.3 and MCA. Positive/negative concordance rate was very good (93.7%) between CA549 and MCA. Conversely, CA15.3 was positive and CA549 negative in 20.4% of cases. Axillary status was not significantly different in the latter group of patients and in cases in which CA15.3 and CA549 showed concordant results. From the present findings we draw the following major conclusions: 1. CA549 and MCA are highly correlated and their association should not provide additional information; however, they should not be considered interchangeable since they may behave differently in individual cases. 2. CA549 and CA15.3, although well correlated, are discordant in a significant number of cases. Longitudinal studies are needed to verify the usefulness of the association between the two markers. 3. The three evaluated mucin markers are not interchangeable in individual patients; if a patient is monitored with a marker, she should be followed up with the same marker.

Full text

PDF
721

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagni B., Cavallini A. R., Indelli M., Malacarne P. Evaluation of CA 549 in malignant neoplasms of the human breast. J Nucl Med Allied Sci. 1990 Oct-Dec;34(4 Suppl):13–16. [PubMed] [Google Scholar]
  2. Barak M., Steiner M., Finkel B., Abrahamson J., Antal S., Gruener N. CA-15.3, TPA and MCA as markers for breast cancer. Eur J Cancer. 1990;26(5):577–580. doi: 10.1016/0277-5379(90)90081-4. [DOI] [PubMed] [Google Scholar]
  3. Bassetto M. A., Franceschi T., Lenotti M., Pancheri F., Zaninelli M., Corgnati A., Cetto G. L. Valore della positività dei marcatori tumorali nei tumori germinali non seminomatosi del testicolo. J Nucl Med Allied Sci. 1990 Oct-Dec;34(4 Suppl):89–90. [PubMed] [Google Scholar]
  4. Bates S. E., Longo D. L. Tumor markers: value and limitations in the management of cancer patients. Cancer Treat Rev. 1985 Sep;12(3):163–207. doi: 10.1016/0305-7372(85)90037-4. [DOI] [PubMed] [Google Scholar]
  5. Bieglmayer C., Szepesi T., Kopp B., Hoffmann G., Petrik W., Guettuoche K., Gründler S., Gregorits M., Strasser M. CA15.3, MCA, CAM26, CAM29 are members of a polymorphic family of mucin-like glycoproteins. Tumour Biol. 1991;12(3):138–148. doi: 10.1159/000217699. [DOI] [PubMed] [Google Scholar]
  6. Bombardieri E., Gion M., Mione R., Dittadi R., Bruscagnin G., Buraggi G. A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancer. Cancer. 1989 Feb 1;63(3):490–495. doi: 10.1002/1097-0142(19890201)63:3<490::aid-cncr2820630317>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  7. Bray K. R., Koda J. E., Gaur P. K. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker. Cancer Res. 1987 Nov 15;47(22):5853–5860. [PubMed] [Google Scholar]
  8. Cazin J. L., Gosselin P., Boniface B., Demaille M. C., Demaille A. An evaluation of CA 549, a circulating marker of breast cancer using a procedure for comparison with CA 15.3. Anticancer Res. 1992 May-Jun;12(3):719–724. [PubMed] [Google Scholar]
  9. Ciatto S., Rosselli Del Turco M., Pacini P., Mustacchi G., Simonis M., Sismondi P., Giardina G., Belsanti V., Aristei C., Molino A. M. Early detection of breast cancer recurrences through periodic follow-up--is it useless? Tumori. 1985 Aug 31;71(4):325–329. doi: 10.1177/030089168507100402. [DOI] [PubMed] [Google Scholar]
  10. Dnistrian A. M., Schwartz M. K., Greenberg E. J., Smith C. A., Schwartz D. C. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. Tumour Biol. 1991;12(2):82–90. doi: 10.1159/000217692. [DOI] [PubMed] [Google Scholar]
  11. Gion M., Mione R., Nascimben O., Valsecchi M., Gatti C., Leon A., Bruscagnin G. The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer. 1991 May;63(5):809–813. doi: 10.1038/bjc.1991.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gion M., Ruggeri G., Mione R., Marconato R., Casella C., Nosadini A., Simoncini E., Belloli S., Dal Zennaro E., Bruscagnin G. A new approach to tumour marker assessment by perioperative determination in breast and colorectal cancer. Int J Biol Markers. 1993 Jan-Mar;8(1):8–13. doi: 10.1177/172460089300800102. [DOI] [PubMed] [Google Scholar]
  13. Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984 Fall;3(3):223–232. doi: 10.1089/hyb.1984.3.223. [DOI] [PubMed] [Google Scholar]
  14. Miserez A. R., Günes I., Müller-Brand J., Walther E., Fridrich R., Mäcke H. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3. Eur J Cancer. 1991;27(2):126–131. doi: 10.1016/0277-5379(91)90468-s. [DOI] [PubMed] [Google Scholar]
  15. Stierer M., Rosen H. R. Influence of early diagnosis on prognosis of recurrent breast cancer. Cancer. 1989 Sep 1;64(5):1128–1131. doi: 10.1002/1097-0142(19890901)64:5<1128::aid-cncr2820640527>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  16. Stähli C., Caravatti M., Aeschbacher M., Kocyba C., Takacs B., Carmann H. Mucin-like carcinoma-associated antigen defined by three monoclonal antibodies against different epitopes. Cancer Res. 1988 Dec 1;48(23):6799–6802. [PubMed] [Google Scholar]
  17. Stähli C., Takacs B., Miggiano V., Staehelin T., Carmann H. Monoclonal antibodies against antigens on breast cancer cells. Experientia. 1985 Nov 15;41(11):1377–1381. doi: 10.1007/BF01949996. [DOI] [PubMed] [Google Scholar]
  18. Sölétormos G., Nielsen D., Schiøler V., Skovsgaard T., Dombernowsky P. Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-up. Eur J Cancer. 1992;28A(4-5):845–850. doi: 10.1016/0959-8049(92)90129-p. [DOI] [PubMed] [Google Scholar]
  19. Zwaveling A., Albers G. H., Felthuis W., Hermans J. An evaluation of routine follow-up for detection of breast cancer recurrences. J Surg Oncol. 1987 Mar;34(3):194–197. doi: 10.1002/jso.2930340314. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES